3-(2-Methyl-1,3-thiazol-4-yl)aniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	736535
CHEMBL ID	1412409
CHEBI ID	194921
SCHEMBL ID	219238

Synonyms (37)

Synonym
EN300-11808
BB 0221282
3-(2-methyl-thiazol-4-yl)-phenylamine
IFLAB1_003704
SDCCGMLS-0012324.P002
OPREA1_237956
IDI1_009811
MLS000102882 ,
smr000015712
4-(3-aminophenyl)-2-methylthiazole, 97%
AKOS000301314
89250-34-0
HMS1422I08
F0804-1565
3-(2-methyl-1,3-thiazol-4-yl)aniline
CHEBI:194921
3-(2-methylthiazol-4-yl)aniline
A843104
4-(3-aminophenyl)-2-methylthiazole
STL163376
HMS2259N09
FT-0613567
SCHEMBL219238
BBL029682
AS-5460
CPHZPWZSSBCSAH-UHFFFAOYSA-N
2-methyl-4-(3-amino-phenyl)-thiazole
3-(2-methylthiazol-4-yl)benzenamine
CHEMBL1412409
56K ,
J-510533
DTXSID40353062
mfcd02579873
AC-9146
Z57984669
2-methyl-4-(3-aminophenyl)thiazole
Q27455508

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	18.9662	0.0447	17.8581	100.0000	AID485294; AID485341
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	22.3872	0.6310	35.7641	100.0000	AID504339
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	3.5481	0.1259	19.1169	125.8920	AID2549
glp-1 receptor, partial	Homo sapiens (human)	Potency	5.0119	0.0184	6.8060	14.1254	AID624417
phosphopantetheinyl transferase	Bacillus subtilis	Potency	100.0000	0.1413	37.9142	100.0000	AID1490
ATAD5 protein, partial	Homo sapiens (human)	Potency	29.0929	0.0041	10.8903	31.5287	AID504467
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	3.9811	0.0013	18.0743	39.8107	AID926
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	0.0065	5.8048	36.1306	65.1308	AID540253
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	29.9349	0.1683	16.4040	67.0158	AID720504
snurportin-1	Homo sapiens (human)	Potency	0.0065	5.8048	36.1306	65.1308	AID540253
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	0.0065	5.8048	16.9962	25.9290	AID540253
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	1.9953	1.9953	25.5327	50.1187	AID624287
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	37.9330	0.0601	10.7453	37.9330	AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Process	via Protein(s)	Taxonomy
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Process	via Protein(s)	Taxonomy
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Process	via Protein(s)	Taxonomy
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (20)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1496252	Inhibition of recombinant human N-terminal His6-tagged BRD4 at 20 uM by TR-FRET assay relative to control	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496256	Binding affinity to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Escherichia coli BL21(DE3) assessed as increase in melting temperature at 50 to 200 uM by differential scanning fluorimetry	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496260	Binding affinity to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 40 uM by differential scanning fluorimetry	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496259	Binding affinity to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 10 uM by differential scanning fluorimetry	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496254	Solubility of the compound in DMSO at 200 mM	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496261	Binding affinity to bovine carbonic anhydrase-2 assessed as change in melting temperature at 20 uM by differential scanning fluorimetry	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1496255	Solubility of the compound in aqueous buffer at 1 mM	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.35 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.30 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gsk525762a molibresib: mimicks acetylated histones; structure in first source	2.17	1	benzodiazepine
pelabresib CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source	2.17	1	monochlorobenzenes; organic heterotricyclic compound; primary carboxamide	antineoplastic agent; bromodomain-containing protein 4 inhibitor
2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide 2-methoxy-N-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide: a probe for bromo and extra C-terminal domain proteins; structure in first source	2.17	1	quinazolines

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

chemdatabank.com